PDS Biotech receives Notice of Allowance for PDS0101 patent.
ByAinvest
Thursday, Jan 22, 2026 8:49 am ET1min read
PDSB--
PDS Biotechnology has received a Notice of Allowance for a patent application for its lead asset, PDS0101. The patent, titled "Methods and Compositions Comprising Cationic Lipids for Stimulating Type I Interferon Genes," will grant broad composition of method of use claims and enhance the company's intellectual property estate. The Versamune platform and PDS0101 value are reinforced as the company advances through late-stage development.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet